Cadario G, Marengo F, Ranghino E, Rossi R, Gatti B, Cantone R, Bona F, Pellegrino R, Feyles G, Puccinelli P, Burastero S E
S.C. Allergologia e Immunologia Clinica, Azienda Ospedaliera S. Giovanni Battista di Torino.
J Investig Allergol Clin Immunol. 2004;14(2):127-33.
Venom immunotherapy has proven a very effective method for the treatment of allergy to Hymenoptera venom. Aqueous instead of depot extracts are prevalently used for this immunotherapy. The advantage of using aqueous extracts has not been fully investigated. We made an open, non-controlled study on 45 subjects sensitized to either Apis mellifera or Vespula spp. Patients were assigned to either a depot (N=27) or an aqueous (N=18) immunotherapy regimen, and side effects were monitored during the induction and the 3-year maintenance phase. The effect of naturally occurring stings during the treatment and after its interruption was recorded as well. Side effects were less frequent with the depot extract both on a "per patient" (22.2% versus 50.0%) and on a "per dose" (2.9% versus 10,2%) basis (p=0.026 and p<0.000, respectively). Better tolerance was mainly due to the lower frequency of local side effects occurring at early times after vaccination. The efficacy of vaccination was comparable in the 2 cohorts, as expected. We conclude that depot immunotherapy to Hymenoptera venom should be preferred to aqueous immunotherapy for the lower occurrence of local side effects. This might influence a better compliance with this potentially life-saving treatment.
毒液免疫疗法已被证明是治疗膜翅目毒液过敏的一种非常有效的方法。这种免疫疗法普遍使用水剂而非长效制剂提取物。使用水剂提取物的优势尚未得到充分研究。我们对45名对意大利蜜蜂或胡蜂属致敏的受试者进行了一项开放性非对照研究。将患者分为长效制剂组(N = 27)或水剂组(N = 18)进行免疫治疗方案,并在诱导期和3年维持期监测副作用。同时记录治疗期间及治疗中断后自然发生的蜇伤的影响。无论是以“每位患者”(22.2%对50.0%)还是以“每剂”(2.9%对10.2%)为基础,长效制剂提取物的副作用发生率都较低(分别为p = 0.026和p < 0.000)。更好的耐受性主要是由于接种疫苗后早期局部副作用的发生率较低。正如预期的那样,两个队列中疫苗接种的疗效相当。我们得出结论,对于膜翅目毒液的免疫治疗,长效制剂免疫疗法应优于水剂免疫疗法,因为其局部副作用发生率较低。这可能会使患者更好地依从这种可能挽救生命的治疗方法。